Scientific Advisory Board

  • Marc Y. Donath, M.D.

    Marc Y. Donath, M.D. is Head of the Clinic for Endocrinology, Diabetes and Metabolism at the University Hospital of Basel, Switzerland, and Professor for Endocrinology at the University of Basel. Dr. Donath is internationally recognized for his contribution to the understanding of the pathogenesis of Type 2 diabetes. His main scientific contribution is the description of an inflammatory process underlying the failure of the pancreatic islet to produce sufficient amount of insulin in Type 2 diabetes. Dr. Donath’s research has contributed to the concept that the innate immune system is part of the regulation of metabolism. He has widely published in journals including the New England Journal of Medicine, Nature, and Cell.

  • Evangelos J. Giamarellos-Bourboulis, M.D., Ph.D

    Evangelos J. Giamarellos-Bourboulis, M.D., Ph.D. is on the Faculty of Medicine of the University of Athens, Greece and has been an Associate Professor of Medicine at the 4th Department of Internal Medicine since 2012. He is an internist and is trained in Clinical Immunology and Infectious Diseases. His main research interests are the immunopathogenesis and immunointervention in sepsis. He has published numerous peer-reviewed manuscripts in this area. Dr. Giamarellos-Bourboulis also has conducted extensive research on inflammatory disorders, including Hidradentitis Suppurativa (HS). He recently completed a Phase II study using Bermekimab to treat moderate to severe HS.

  • Alice Gottlieb, M.D., Ph.D.

    Dr. Gottlieb is currently Professor of Dermatology at New York Medical College and former Chair of Dermatology and Dermatologist-in-Chief at the Tufts Medical Center and Tufts University School of Medicine. Dr. Gottlieb was elected to the Board of Directors of the American Academy of Dermatology from 2011-2015 and is the Founder and President of the Board of the International Dermatology Outcome Measures group and co-Editor-in-Chief of the Journal of Psoriasis and Psoriatic Arthritis. Dr. Gottlieb has authored 400 publications and presented her research at more than 200 conferences across the globe. She is triple-boarded in dermatology, rheumatology and internal medicine, one of only a handful of doctors in the U.S. certified in all three specialties. She obtained her M.D. from Cornell Medical School and her Ph.D. in immunology from the Rockefeller University.

  • Andrew Hendifar, M.D.

    Andrew Hendifar, M.D., is the medical oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and co-director of Pancreas Oncology. He and his colleagues from Surgery, Gastroenterology, Radiation Oncology and Radiology have formed multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors.

    Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine and pancreatic cancer. He also conducts research involving cachexia in cancer patients, and has developed a treatment protocol in pancreatic cancer cachexia. Dr. Hendifar is the primary investigator for several trials in the treatment of pancreatic cancer, colon cancer, and neuroendocrine tumors.

    Dr. Hendifar's work has been published in prestigious journals, including the Lancet, Cancer, Journal of Clinical Oncology, and Clinical Cancer Research. Dr. Hendifar has displayed deep subject-matter knowledge in presentations for organizations such as the National Institutes of Health and the American Society of Clinical Oncology. His patient care has also been recognized, as he was named a "Top Doctor" in 2010 and has been listed a "Super Doctor” since 2013.

  • Alexander Knuth, M.D.

    Alexander Knuth, M.D. is the Medical Director and Chief Executive Officer of the National Center for Cancer Care and Research at Hamad Medical Corporation. Dr. Knuth’s pioneering work in cancer immunology led to the discovery of multiple human cancer antigens including MAGE, the first of the so-called cancer/testis (CT) antigens that have been a primary target of vaccine strategies to date. He also played a pivotal role in the development of peptide-based vaccines and adjuvants, established immune-monitoring techniques, and discovered tumor escape mechanisms. He has received many awards, including the prestigious Johann-Georg-Zimmermann Medal. Dr. Knuth is a member of the Cancer Research Institute’s (CRI) Scientific Advisory Council, serves on the CLIP Grant Review Committee and is a member of CRI’s global clinical investigator network.

  • Razelle Kurzrock, M.D.

    Razelle Kurzrock, M.D., is a board-certified medical oncologist and a renowned expert in precision medicine. Dr. Kurzrock currently serves as Senior Deputy Center Director for Clinical Science, Director at the Center for Personalized Cancer Therapy, Director of the Clinical Trials Office, and a Team Leader for Experimental Therapeutics at the Moores Cancer Center at UC San Diego. Dr. Kurzrock is known for developing one of the largest and best Phase 1 clinical trials programs in the nation while at the University of Texas MD Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT (Profile-Related Evidence Determining Individualized Cancer Therapy). This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized chances for response.

    Dr. Kurzrock has a strong history of building outstanding education/training programs. At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigational Cancer Therapeutics. At UCSD Moores Cancer, she founded and directs the Fellowship in Personalized Cancer Therapy.

    Dr. Kurzrock is also Chief of the Hematology & Oncology Division in the UC San Diego School of Medicine. She is a frequent speaker at national and international meetings, and her research has been widely published, with more than 600 peer-reviewed publications. Dr. Kurzrock earned her medical degree from the University of Toronto. She completed her residency at Tulane University and her fellowship in medical oncology at the University of Texas MD Anderson Cancer Center. She is board certified in internal medicine and medical oncology.

  • William Levis, M.D.

    Dr. Levis serves as Chairman of the Foundation for Global Skin Health Strategies and Lifetime Professor of Dermatology, Rockefeller University. He is presently Attending Physician, New York Hansen’s Disease Program, Bellevue Hospital Center, New York, NY. In 2008, he opened the Levis Dermatology private practice in New York City. He has held several positions with the National Cancer Institute including an appointment as Senior Investigator, Dermatology Branch. He also served for a period as the Chief of the department of Dermatology at US Public Health Service in Staten Island. Dr. Levis then went on to serve as Medical Specialist at the New York State Institute for Basic Research in Developmental Disabilities and has held the positions of Adjunct Professor of Dermatology, New York Medical College and Adjunct Professor of Medicine, Cornell University Medical College. Dr. Levis has extensive publications and has presented many lectures at venues around the world. In 2008, he was honored with the prestigious Astellas Award for Public Health. Dr. Levis was also awarded the Meritorious Service Medal, which is the silver star of the U.S. Public Health Service (USPHS). Dr. Levis is a member of the American Society of Clinical Investigation. Today he is engaged in the research and clinical development of new immunomodulator technologies for the treatment of dermatological conditions.

  • Peter Libby, M.D.

    Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He served as Chief of Cardiovascular Medicine at BWH from 1998 - 2014. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate his basic laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials. He instigated and helped to lead the large scale Canakinumab Anti-Inflammatory Thrombosis Outcomes Trial that provided clinical validation of the role of inflammation in atherosclerosis.

    Dr. Libby has received numerous awards and recognitions for his research accomplishments, including most recently the Gold Medal of the European Society of Cardiology (2011), the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), and the Special Award of the Heart Failure Association of the European Society of Cardiology (2014). He has received a number of lifetime achievement awards various organizations. Dr. Libby was selected as Consulting Editor of the year by Circulation Research in 2015, and received a 2015 High Citation Award as an editorial board member of Arteriosclerosis Thrombosis, and Vascular Biology. He was the laureate of the Ernst Jung Gold Medal for Medicine for 2016, and received the Earl Benditt Award from the North American Vascular Biology Organization in 2017. In 2018 he received the Arthur Agaston Award for Preventive Cardiology and an honorary doctorate degree from the Université Laval.

    Dr. Libby’s elected professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and honorary memberships in the British Atherosclerosis Society, the Japan Circulation Society, and the Japanese College of Cardiology. He has served as the President of the Association of University Cardiologists. He also has served in many roles as a volunteer for the American Heart Association, including chairman of several research committees and member of the executive committees of the Councils on Arteriosclerosis, Circulation, and Basic Science. He presided the American College of Cardiology’s Research Allocations Peer Review Committee for two terms. He has frequently consulted for the National Heart, Lung, and Blood Institute, including a 5-year term on the Board of Scientific Councilors. He directed the DW Reynolds Cardiovascular Clinical Research Center and two cycles of Leducq Foundation Awards, and has received continuous funding from the US National Heart Lung and Blood Institute (NHLBI) for several decades.

    An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is an Editor of Braunwald’s Heart Disease, having served as the Editor-in Chief of the 8th Edition. Dr. Libby has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison’s Principles of Internal Medicine. He has held numerous visiting professorships and delivered more than 100 major named or keynote lectures throughout the world. Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital). He also holds an honorary MA degree from Harvard University, and an honorary doctorate from the University of Lille, France.

  • Mark E. Rupp, M.D.

    Dr. Mark E. Rupp is a Professor and Chief of the Division of Infectious Diseases in the Department of Internal Medicine at the University of Nebraska Medical Center. He is also the Medical Director of The Nebraska Medical Center Department of Infection Control & Epidemiology.

    Dr. Rupp received his medical degree from Baylor College of Medicine in Houston, Texas and holds a B.S. degree in Chemical Engineering from the University of Texas at Austin. He completed internship and residency training in Internal Medicine and a Fellowship in Infectious Diseases at Virginia Commonwealth University in Richmond, Virginia.

    Dr. Rupp is a Diplomate of the American Board of Internal Medicine in the subspecialty area of Infectious Diseases. Dr. Rupp is a Fellow of the American College of Physicians (FACP), the Infectious Diseases Society of America (IDSA), and the Society for Hospital Epidemiology of America (SHEA). Dr. Rupp is a member of the International Society on Staphylococci and Staphylococcal Infections. He is a Past-President of SHEA and a past-president of the American Society for Microbiology Division L (Infection Control/Hospital Epidemiology). Dr. Rupp has served as a consultant for the US Food and Drug Administration as well as the Centers for Disease Control and Prevention, National Institutes of Health, and the US Department of Veteran Affairs.

    Dr. Rupp has published over 300 articles, chapters and abstracts. He frequently presents papers at national and international conferences, serves as a guest lecturer, and is an active teacher and researcher. Dr. Rupp’s research interests are in the areas of staphylococcal disease, healthcare-associated infections, and antimicrobial resistance.